{ }
Benedikt Schuppli, co-founder of Obligate, is launching Margarita Finance to bring structured financial products, dubbed "degen products of TradFi," to the crypto space. Users can invest with a minimum of 10 USDC, customizing their yield and maturity while benefiting from reduced fees through blockchain technology. Margarita aims to simplify the often complex world of DeFi structured products, with plans to evolve into a DAO post-launch.
Three UBS advisor teams have been recognized in Forbes' 2024 America’s Top Wealth Management Teams Private Wealth list: Wickham Cash Partners, LongBernsteinGunderson Wealth Management, and The Capital ESOP Group. These teams, part of the Philadelphia D.C. Wealth Management Market, collectively manage over $490 billion in assets, showcasing their expertise in guiding ultra-high net worth clients.
Billionaire Ray Dalio warns of an impending debt crisis in major economies, advocating for "hard money" like Bitcoin and gold over bonds. Despite Bitcoin's potential as a store of value, he remains skeptical about its effectiveness and the risk of government crackdowns on cryptocurrencies. As inflation persists, gold has reached record highs, while Bitcoin struggles to keep pace, raising questions about its long-term viability as a safe investment.
The stock market exhibits anomalies like the January Effect, where small-cap stocks often see price increases in January due to factors like tax-loss harvesting and year-end bonuses. However, this effect has weakened since its discovery, with recent data showing minimal or negative returns for January, suggesting that pricing inefficiencies have largely been arbitraged away. Investors are advised to focus on long-term, diversified strategies rather than short-term trends.
William Blair forecasts CRISPR Therapeutics will report FY2024 earnings of ($4.66) per share, slightly better than the consensus estimate of ($5.17). The company recently posted Q3 earnings of ($1.01) per share, exceeding expectations, but reported revenues significantly below estimates. Analysts maintain a "Hold" rating on the stock, with a mixed outlook reflected in various price targets.
B2TRADER, launched by B2BROKER, is a pioneering multi-asset trading platform that integrates crypto spot, Forex, CFDs, and crypto derivatives into a single account. With an investment of $8 million and 2.5 years of development, it offers brokers customizable solutions, enhanced performance, and mobile trading apps for iOS and Android. The platform aims to bridge the gap between Forex and crypto markets, supporting brokers in expanding their offerings and managing risks effectively.
BMO Capital Markets has raised Novartis' price target from $118 to $120, maintaining a "market perform" rating. Currently, the stock holds a consensus "Hold" rating with an average target price of $121.50, while institutional investors own 13.12% of the shares. Novartis reported a Q3 EPS of $2.06, surpassing estimates, with revenue of $12.82 billion.
BMO Capital Markets raised Novartis' price target from $118 to $120, maintaining a "market perform" rating. The stock has an average "Hold" rating from analysts, with a consensus price target of $121.50. Recently, Novartis reported earnings of $2.06 per share, exceeding estimates, and had a revenue of $12.82 billion for the quarter.
BYDFi has launched an upgraded Perpetual Trading System, enhancing core functionalities and introducing innovative features such as using unrealized profits as margin for new positions, a new hedging function for risk management, and a Cross Margin mode to reduce liquidation risks. The platform aims to improve user experience and trading security, with a focus on continuous interaction with users to adapt to market needs. Users can access the new features through the upgraded trading interface on the BYDFi website or app.
JPMorgan Chase & Co. lowered its price target for ASML from $1,207 to $1,148, maintaining an "overweight" rating, while UBS downgraded the stock from "buy" to "neutral." ASML has an average rating of "Moderate Buy" with a consensus target price of $943.83, as three analysts hold a "hold" rating, ten a "buy," and two a "strong buy." The company recently reported earnings of $5.80 per share, exceeding estimates, and announced a quarterly dividend of $1.407, reflecting a yield of 0.79%.
Trending
Subcategory:
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.